pdf   xlsx method abbreviations

ovarian cancer (OC), atezolizumab plus SoC , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.96 [0.74, 1.25]< 10%1 study (1/-)61.8 %NAnot evaluable crucial-
progression or deaths (PFS) 0.92 [0.79, 1.07]< 10%1 study (1/-)85.9 %NAnot evaluable important-
objective responses (ORR) 1.65 [0.88, 3.08]> 10%1 study (1/-)94.2 %NAnot evaluable non important-

safety endpoints 00

TRAE (grade 3-4) endpoints 00

Adrenal insufficiency TRAE (grade 3-4) 1.00 [0.02, 50.63]< 10%1 study (1/-)49.9 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 2.52 [0.49, 13.03]< 10%1 study (1/-)13.6 %NAnot evaluable non important-
Diabetes TRAE (grade 3-4) 2.01 [0.07, 59.96]< 10%1 study (1/-)34.6 %NAnot evaluable non important-
Guillain-Barré syndrome TRAE (grade 3-4) 1.00 [0.06, 16.07]< 10%1 study (1/-)49.9 %NAnot evaluable non important-
Hepatitis TRAE (grade 3-4) 1.76 [0.51, 6.05]< 10%1 study (1/-)18.4 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 3.02 [0.31, 29.10]< 10%1 study (1/-)17.1 %NAnot evaluable non important-
Infusion-related reactions TRAE (grade 3-4) 2.01 [0.07, 59.96]< 10%1 study (1/-)34.6 %NAnot evaluable non important-
Myocarditis TRAE (grade 3-4) 0.50 [0.02, 14.97]< 10%1 study (1/-)65.3 %NAnot evaluable non important-
Myositis TRAE (grade 3-4) 6.04 [0.30, 120.87]< 10%1 study (1/-)12.2 %NAnot evaluable non important-
Nephritis TRAE (grade 3-4) 2.01 [0.07, 59.96]< 10%1 study (1/-)34.6 %NAnot evaluable non important-
Pancreatitis TRAE (grade 3-4) 8.07 [0.43, 152.94]< 10%1 study (1/-)8.4 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 2.01 [0.07, 59.96]< 10%1 study (1/-)34.6 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 1.59 [0.61, 4.12]< 10%1 study (1/-)17.2 %NAnot evaluable non important-
Severe skin reaction TRAE (grade 3-4) 7.25 [3.06, 17.21]< 10%1 study (1/-)0.0 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

Acute kidney injury AE (grade 3-4) 2.01 [0.37, 11.03]< 10%1 study (1/-)21.1 %NAnot evaluable non important-
Decreased appetite AE (grade 3-4) 0.83 [0.25, 2.75]< 10%1 study (1/-)61.7 %NAnot evaluable non important-
Dyspnoea AE (grade 3-4) 2.52 [0.49, 13.03]< 10%1 study (1/-)13.6 %NAnot evaluable non important-
Hypertension AE (grade 3-4) 0.88 [0.67, 1.16]< 10%1 study (1/-)81.3 %NAnot evaluable non important-
Infusion-related reaction AE (grade 3-4) 3.03 [0.61, 15.06]< 10%1 study (1/-)8.9 %NAnot evaluable non important-
Proteinuria AE (grade 3-4) 0.60 [0.31, 1.18]< 10%1 study (1/-)93.0 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons